Nuclear factor-κB (NF-κB): An unsuspected major culprit in the pathogenesis of endometriosis that is still at large?

Gynecologic and Obstetric Investigation

Volumn 63, Issue 2, 2007, Pages 71-97

  Guo, Sun Wei ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Angiogenesis; Apoptosis; Cytokine, endometriosis; Inflammation; Invasion; NF B; Pathogenesis; Pelvic pain; Progesterone receptor; Proliferation

Indexed keywords

11BETA (4 ACETYLPHENYL) 17BETA HYDROXY 17ALPHA (1,1,2,2,2 PENTAFLUOROETHYL)ESTRA 4,9 DIEN 3 ONE; 2 (3 FLUORO 4 HYDROXYPHENYL) 7 VINYL 5 BENZOXAZOLOL; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL SUCCINATE; ANTIINFLAMMATORY AGENT; AROMATASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DANAZOL; GLUCOCORTICOID; GONADORELIN AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MG 312; MIFEPRISTONE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PROGESTERONE RECEPTOR MODULATOR; PROTEASOME INHIBITOR; RAXOFELAST; SALICYLATE SODIUM; SN 50; SULINDAC; THALIDOMIDE; TRANSCRIPTION FACTOR; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; WAY 169916; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR B;

ANGIOGENESIS; APOPTOSIS; CELL ACTIVATION; CELL INVASION; CELL PROLIFERATION; CELL TRANSFORMATION; ENDOMETRIOSIS; ENDOMETRIUM; GENE; HUMAN; IMMUNOCYTOCHEMISTRY; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RED WINE; REVIEW; FEMALE; METABOLISM;

ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; HUMANS; NF-KAPPA B; RECEPTORS, PROGESTERONE;

EID: 33846977747     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096047     Document Type: Review

References (419)

1. Mahmood TA, Templeton A: Prevalence and genesis of endometriosis. Hum Reprod 1991;6:544-549.
2. Olive DL, Schwartz LB: Endometriosis. N Engl J Med 1993;328:1759-1769.
3. Farquhar CM: Extracts from the 'clinical evidence'. Endometriosis. BMJ 2000;320:1449-1452.
4. Kitawaki J, Kado N, Ishihara H, Koshiba H, Kitaoka Y, Honjo H: Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biochem Mol Biol 2002;83:149-155.
5. Gurates B, Bulun SE: Endometriosis: the ultimate hormonal disease. Semin Reprod Med 2003;21:125-134.
6. Olive DL, Pritts EA: Treatment of endometriosis. N Engl J Med 2001;345:266-275.
7. Lessey BA: Medical management of endometriosis and infertility. Fertil Steril 2000;73:1089-1096.
8. Valle RF, Sciarra JJ: Endometriosis: treatment strategies. Ann NY Acad Sci 2003;997:229-239.
9. Ho HN, Wu MY, Yang YS: Peritoneal cellular immunity and endometriosis. Am J Reprod Immunol 1997;38:400-412.
10. Akoum A, Kong J, Metz C, Beaumont MC: Spontaneous and stimulated secretion of monocyte chemotactic protein-1 and macrophage migration inhibitory factor by peritoneal macrophages in women with and without endometriosis. Fertil Steril 2002;77:989-994.
11. Akoum A, Lemay A, McColl SR, Paradis I, Maheux R: Increased monocyte chemotactic protein-1 level and activity in the peripheral blood of women with endometriosis. Le Groupe d'Investigation en Gynecologie. Am J Obstet Gynecol 1996;175:1620-1625.
12. Arici A, Tazuke SI, Attar E, Kliman HJ, Olive DL: Interleukin-8 concentration in peritoneal fluid of patients with endometriosis and modulation of interleukin-8 expression in human mesothelial cells. Mol Hum Reprod 1996;2:40-45.
13. Eisermann J, Gast MJ, Pineda J, Odem RR, Collins JL: Tumor necrosis factor in peritoneal fluid of women undergoing laparoscopic surgery. Fertil Steril 1988;50:573-579.
14. Arici A, MacDonald PC, Casey ML: Regulation of monocyte chemotactic protein-1 gene expression in human endometrial cells in cultures. Mol Cell Endocrinol 1995;107:189-197.
15. Punnonen J, Teisala K, Ranta H, Bennett B, Punnonen R: Increased levels of interleukin-6 and interleukin-10 in the peritoneal fluid of patients with endometriosis. Am J Obstet Gynecol 1996;174:1522-1526.
16. Rana N, Braun DP, House R, Gebel H, Rotman C, Dmowski WP: Basal and stimulated secretion of cytokines by peritoneal macrophages in women with endometriosis. Fertil Steril 1996;65:925-930.
17. Koninckx PR, Kennedy SH, Barlow DH: Endometriotic disease: the role of peritoneal fluid. Hum Reprod Update 1998;4:741-751.
18. Kim JG, Suh CS, Kim SH, Choi YM, Moon SY, Lee JY: Insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP-3 protease activity in the peritoneal fluid of patients with and without endometriosis. Fertil Steril 2000;73:996-1000.
19. Gurgan T, Bukulmez O, Yarali H, Tanir M, Akyildiz S: Serum and peritoneal fluid levels of IGF I and II and insulinlike growth binding protein-3 in endometriosis. J Reprod Med 1999;44:450-454.
20. Richter O, Mallmann P, van der Ven H, Krebs D: TNF-α secretion by peritoneal macrophages in endometriosis. Zentralbl Gynakol 1998;120:332-336.
21. Braun DP, Gebel H, House R, Rana N, Dmowski NP: Spontaneous and induced synthesis of cytokines by peripheral blood monocytes in patients with endometriosis. Fertil Steril 1996;65:1125-1129.
22. Bullimore DW: Endometriosis is sustained by tumour necrosis factor-α. Med Hypotheses 2003;60:84-88.
23. Arici A: Local cytokines in endometrial tissue: The role of interleukin-8 in the pathogenesis of endometriosis. Ann NY Acad Sci 2002;955:101-109; discussion 18, 396-406.
24. Hornung D, Klingel K, Dohrn K, Kandolf R, Wallwiener D, Taylor RN: Regulated on activation, normal T-cell-expressed and -secreted mRNA expression in normal endometrium and endometriotic implants: assessment of autocrine/paracrine regulation by in situ hybridization. Am J Pathol 2001;158:1949-1954.
25. Akoum A, Lemay A, Brunet C, Hebert J: Cytokine-induced secretion of monocyte chemotactic protein-1 by human endometriotic cells in culture. The Groupe d'Investigation en Gynecologie. Am J Obstet Gynecol 1995;172(pt 1):594-600.
26. Akoum A, Lemay A, Paradis I, Rheault N, Maheux R: Secretion of interleukin-6 by human endometriotic cells and regulation by proinflammatory cytokines and sex steroids. Hum Reprod 1996;11:2269-2275.
27. Faber BM, Chegini N, Mahony MC, Coddington CC 3rd: Macrophage secretory products and sperm zona pellucida binding. Obstet Gynecol 2001;98:668-673.
28. Carlberg M, Nejaty J, Froysa B, Guan Y, Soder O, Bergqvist A: Elevated expression of tumour necrosis factor α in cultured granulosa cells from women with endometriosis. Hum Reprod 2000;15:1250-1255.
29. Lee KS, Joo BS, Na YJ, Yoon MS, Choi OH, Kim WW: Relationships between concentrations of tumor necrosis factor-α and nitric oxide in follicular fluid and oocyte quality. J Assist Reprod Genet 2000;17:222-228.
30. Pellicer A, Navarro J, Bosch E, et al: Endometrial quality in infertile women with endometriosis. Ann NY Acad Sci 2001;943:122-130.
31. Halis G, Arici A: Endometriosis and inflammation in infertility. Ann NY Acad Sci 2004;1034:300-315.
32. Thomson JC, Redwine DB: Chronic pelvic pain associated with autoimmunity and systemic and peritoneal inflammation and treatment with immune modification. J Reprod Med 2005;50:745-758.
33. Agic A, Xu H, Finas D, Banz C, Diedrich K, Hornung D: Is endometriosis associated with systemic subclinical inflammation? Gynecol Obstet Invest 2006;62:139-147.
34. Kao LC, Germeyer A, Tulac S, et al: Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility. Endocrinology 2003;144:2870-2881.
35. Matsuzaki S, Canis M, Vaurs-Barriere C, Boespflug-Tanguy O, Dastugue B, Mage G: DNA microarray analysis of gene expression in eutopic endometrium from patients with deep endometriosis using laser capture microdissection. Fertil Steril 2005;84(suppl 2):1180-1190.
36. Wu Y, Kajdacsy-Balla A, Strawn E, et al: Transcriptional characterizations of differences between eutopic and ectopic endometrium. Endocrinology 2006;147:232-246.
37. Van Langendonckt A, Casanas-Roux F, Donnez J: Oxidative stress and peritoneal endometriosis. Fertil Steril 2002;77:861-870.
38. Yamauchi N, Harada T, Taniguchi F, Yoshida S, Iwabe T, Terakawa N: Tumor necrosis factor-α induced the release of interleukin-6 from endometriotic stromal cells by the nuclear factor-κB and mitogen-activated protein kinase pathways. Fertil Steril 2004;82(suppl 3):1023-1028.
39. Wu MH, Wang CA, Lin CC, Chen LC, Chang WC, Tsai SJ: Distinct regulation of cyclooxygenase-2 by interleukin-1β in normal and endometriotic stromal cells. J Clin Endocrinol Metab 2005;90:286-295.
40. Bulun SE, Lin Z, Imir G, et al: Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 2005;57:359-383.
41. Bulun SE, Yang S, Fang Z, et al: Role of aromatase in endometrial disease. J Steroid Biochem Mol Biol 2001;79:19-25.
42. Tsai SJ, Wu MH, Lin CC, Sun HS, Chen HM: Regulation of steroidogenic acute regulatory protein expression and progesterone production in endometriotic stromal cells. J Clin Endocrinol Metab 2001;86:5765-5773.
43. Zeitoun K, Takayama K, Sasano H, et al: Deficient 17β-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17β-estradiol. J Clin Endocrinol Metab 1998;83:4474-4480.
44. Sun HS, Hsiao KY, Hsu CC, Wu MH, Tsai SJ: Transactivation of steroidogenic acute regulatory protein in human endometriotic stromal cells is mediated by the prostaglandin EP2 receptor. Endocrinology 2003;144:3934-3942.
45. Odukoya OA, Ajjan R, Lim K, Watson PF, Weetman AP, Cooke ID: The pattern of cytokine mRNA expression in ovarian endometriomata. Mol Hum Reprod 1997;3:393-397.
46. Ho HN, Wu MY, Chao KH, et al: Decrease in interferon γ production and impairment of T-lymphocyte proliferation in peritoneal fluid of women with endometriosis. Am J Obstet Gynecol 1996;175:1236-1241.
47. Taketani Y, Kuo TM, Mizuno M: Comparison of cytokine levels and embryo toxicity in peritoneal fluid in infertile women with untreated or treated endometriosis. Am J Obstet Gynecol 1992;167:265-270.
48. Fakih H, Baggett B, Holtz G, Tsang KY, Lee JC, Williamson HO: Interleukin-1: a possible role in the infertility associated with endometriosis. Fertil Steril 1987;47:213-217.
49. Bedaiwy MA, Falcone T, Sharma RK, et al: Prediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial. Hum Reprod 2002;17:426-431.
50. Wu MY, Chao KH, Chen SU, et al: The suppression of peritoneal cellular immunity in women with endometriosis could be restored after gonadotropin releasing hormone agonist treatment. Am J Reprod Immunol 1996;35:510-516.
51. McLaren J, Prentice A, Charnock-Jones DS, Smith SK: Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod 1996;11:220-223.
52. Shifren JL, Tseng JF, Zaloudek CJ, et al: Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: Implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J Clin Endocrinol Metab 1996;81:3112-3118.
53. Wu MY, Ho HN: The role of cytokines in endometriosis. Am J Reprod Immunol 2003;49:285-296.
54. Ryan IP, Taylor RN: Endometriosis and infertility: new concepts. Obstet Gynecol Surv 1997;52:365-371.
55. Giudice LC, Kao LC: Endometriosis. Lancet 2004;364:1789-1799.
56. Osteen KG, Bruner-Tran KL, Eisenberg E: Reduced progesterone action during endometrial maturation: a potential risk factor for the development of endometriosis. Fertil Steril 2005;83:529-537.
57. Bruner-Tran KL, Eisenberg E, Yeaman GR, Anderson TA, McBean J, Osteen KG: Steroid and cytokine regulation of matrix metalloproteinase expression in endometriosis and the establishment of experimental endometriosis in nude mice. J Clin Endocrinol Metab 2002;87:4782-4791.
58. Osteen KG, Bruner-Tran KL, Keller NR, Eisenberg E: Progesterone-mediated endometrial maturation limits matrix metalloproteinase (MMP) expression in an inflammatory-like environment: a regulatory system altered in endometriosis. Ann NY Acad Sci 2002;955:37-47; discussion 86-88, 396-406.
59. Curry TE Jr, Osteen KG: The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr Rev 2003;24:428-465.
60. Bruner KL, Matrisian LM, Rodgers WH, Gorstein F, Osteen KG: Suppression of matrix metalloproteinases inhibits establishment of ectopic lesions by human endometrium in nude mice. J Clin Invest 1997;99:2851-2857.
61. Cox KE, Piva M, Sharpe-Timms KL: Differential regulation of matrix metalloproteinase-3 gene expression in endometriotic lesions compared with endometrium. Biol Reprod 2001;65:1297-1303.
62. Scotti S, Regidor PA, Schindler AE, Winterhager E: Reduced proliferation and cell adhesion in endometriosis. Mol Hum Reprod 2000;6:610-617.
63. Beliard A, Noel A, Foidart JM: Reduction of apoptosis and proliferation in endometriosis. Fertil Steril 2004;82:80-85.
64. Gebel HM, Braun DP, Tambur A, Frame D, Rana N, Dmowski WP: Spontaneous apoptosis of endometrial tissue is impaired in women with endometriosis. Fertil Steril 1998;69:1042-1047.
65. Izawa M, Harada T, Deura I, Taniguchi F, Iwabe T, Terakawa N: Drug-induced apoptosis was markedly attenuated in endometriotic stromal cells. Hum Reprod 2006;21:600-604.
66. Starzinski-Powitz A, Zeitvogel A, Schreiner A, Baumann R: In search of pathogenic mechanisms in endometriosis: the challenge for molecular cell biology. Curr Mol Med 2001;1:655-664.
67. Redwine DB: Age-related evolution in color appearance of endometriosis. Fertil Steril 1987;48:1062-1063.
68. Gaetje R, Kotzian S, Herrmann G, Baumann R, Starzinski-Powitz A: Nonmalignant epithelial cells, potentially invasive in human endometriosis, lack the tumor suppressor molecule E-cadherin. Am J Pathol 1997;150:461-467.
69. Ota H, Igarashi S, Hatazawa J, Tanaka T: Endometriosis and free radicals. Gynecol Obstet Invest 1999;48(suppl 1):29-35.
70. Santanam N, Murphy AA, Parthasarathy S: Macrophages, oxidation, and endometriosis. Ann NY Acad Sci 2002;955:183-198; discussion 19-200, 396-406.
71. Jackson LW, Schisterman EF, Dey-Rao R, Browne R, Armstrong D: Oxidative stress and endometriosis. Hum Reprod 2005;20:2014-2020.
72. Kao SH, Huang HC, Hsieh RH, Chen SC, Tsai MC, Tzeng CR: Oxidative damage and mitochondrial DNA mutations with endometriosis. Ann NY Acad Sci 2005;1042:186-194.
73. Slater M, Quagliotto G, Cooper M, Murphy CR: Endometriotic cells exhibit metaplastic change and oxidative DNA damage as well as decreased function, compared to normal endometrium. J Mol Histol 2005;36:257-263.
74. Santanam N, Song M, Rong R, Murphy AA, Parthasarathy S: Atherosclerosis, oxidation and endometriosis. Free Radic Res 2002;36:1315-1321.
75. Surh Y-J, Packer L: Oxidative Stress, Inflammation, and Health. New York, Taylor and Francis, 2005.
76. Agarwal A, Gupta S, Sharma RK: Role of oxidative stress in female reproduction. Reprod Biol Endocrinol 2005;3:28.
77. Jiang X, Hitchcock A, Bryan EJ, et al: Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Cancer Res 1996;56:3534-3539.
78. Goumenou AG, Arvanitis DA, Matalliotakis IM, Koumantakis EE, Spandidos DA: Loss of heterozygosity in adenomyosis on hMSH2, hMLH1, p16Ink4 and GALT loci. Int J Mol Med 2000;6:667-671.
79. Obata K, Hoshiai H: Common genetic changes between endometriosis and ovarian cancer. Gynecol Obstet Invest 2000;50(suppl 1):39-43.
80. Gogusev J, Bouquet de Joliniere J, Telvi L, et al: Genetic abnormalities detected by comparative genomic hybridization in a human endometriosis-derived cell line. Mol Hum Reprod 2000;6:821-827.
81. Bischoff FZ, Heard M, Simpson JL: Somatic DNA alterations in endometriosis: high frequency of chromosome 17 and p53 loss in late-stage endometriosis. J Reprod Immunol 2002;55:49-64.
82. Wu Y, Strawn E, Basir Z, et al: Genomic alterations in the ectopic and eutopic endometrium of women with endometriosis. Gynecol Obstet Invest 2006;62:148-159.
83. Guo SW, Wu Y, Strawn E, et al: Genomic alterations in the endometrium may be a proximate cause for endometriosis. Eur J Obstet Gynecol Reprod Biol 2004;116:89-99.
84. Starzinski-Powitz A, Gaetje R, Zeitvogel A, et al: Tracing cellular and molecular mechanisms involved in endometriosis. Hum Reprod Update 1998;4:724-729.
85. Liotta LA, Stetler-Stevenson WG: Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991;51(suppl):5054s- 5059s.
86. Spuijbroek MD, Dunselman GA, Menheere PP, Evers JL: Early endometriosis invades the extracellular matrix. Fertil Steril 1992;58:929-933.
87. Zeitvogel A, Baumann R, Starzinski-Powitz A: Identification of an invasive, N-cadherinexpressing epithelial cell type in endometriosis using a new cell culture model. Am J Pathol 2001;159:1839-1852.
88. Jiang J, Wu RF, Wang ZH, Sun HC, Xu Z, Xiu HM: Effect of mifepristone on estrogen and progesterone receptors in human endometrial and endometriotic cells in vitro. Fertil Steril 2002;77:995-1000.
89. Kumar A, Takada Y, Boriek AM, Aggarwal BB: Nuclear factor-κB: Its role in health and disease. J Mol Med 2004;82:434-448.
90. Ghosh S, May MJ, Kopp EB: NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-260.
91. Wilkinson KD: Signal transduction: aspirin, ubiquitin and cancer. Nature 2003;424:738-739.
92. Finco TS, Beg AA, Baldwin AS Jr: Inducible phosphorylation of IκBα is not sufficient for its dissociation from NF-κB and is inhibited by protease inhibitors. Proc Natl Acad Sci USA 1994;91:11884-11888.
93. Baldi L, Brown K, Franzoso G, Siebenlist U: Critical role for lysines 21 and 22 in signalinduced, ubiquitin-mediated proteolysis of I κBα. J Biol Chem 1996;271:376-379.
94. Roff M, Thompson J, Rodriguez MS, et al: Role of IκBα ubiquitination in signal-induced activation of NFκB in vivo. J Biol Chem 1996;271:7844-7850.
95. Chen ZJ, Parent L, Maniatis T: Site-specific phosphorylation of IκBα by a novel ubiquitination-dependent protein kinase activity. Cell 1996;84:853-862.
96. Karin M, Takahashi T, Kapahi P, et al: Oxidative stress and gene expression: the AP-1 and NF-κB connections. Biofactors 2001;15:87-89.
97. Zhou LZ, Johnson AP, Rando TA: NF κB and AP-1 mediate transcriptional responses to oxidative stress in skeletal muscle cells. Free Radic Biol Med 2001;31:1405-1416.
98. Zhong H, May MJ, Jimi E, Ghosh S: The phosphorylation status of nuclear NF-κB determines its association with CBP/p300 or HDAC-1. Mol Cell 2002;9:625-636.
99. Pomerantz JL, Baltimore D: Two pathways to NF-κB. Mol Cell 2002;10:693-695.
100. Senftleben U, Cao Y, Xiao G, et al: Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science 2001;293:1495-1499.
101. Laird SM, Tuckerman EM, Cork BA, Li TC: Expression of nuclear factor κB in human endometrium; role in the control of interleukin 6 and leukaemia inhibitory factor production. Mol Hum Reprod 2000;6:34-40.
102. Page M, Tuckerman EM, Li TC, Laird SM: Expression of nuclear factor κB components in human endometrium. J Reprod Immunol 2002;54:1-13.
103. May MJ, Ghosh S: Signal transduction through NF-κB. Immunol Today 1998;19:80-88.
104. King AE, Critchley HO, Kelly RW: The NF-κB pathway in human endometrium and first trimester decidua. Mol Hum Reprod 2001;7:175-183.
105. Finn CA: Implantation, menstruation and inflammation. Biol Rev Camb Philos Soc 1986;61:313-328.
106. Kelly RW: Pregnancy maintenance and parturition: the role of prostaglandin in manipulating the immune and inflammatory response. Endocr Rev 1994;15:684-706.
107. Tabibzadeh S, Sun XZ: Cytokine expression in human endometrium throughout the menstrual cycle. Hum Reprod 1992;7:1214-1221.
108. Tabibzadeh S, Zupi E, Babaknia A, Liu R, Marconi D, Romanini C: Site and menstrual cycle-dependent expression of proteins of the tumour necrosis factor (TNF) receptor family, and BCL-2 oncoprotein and phase-specific production of TNF α in human endometrium. Hum Reprod 1995;10:277-286.
109. Baird DT, Cameron ST, Critchley HO, et al: Prostaglandins and menstruation. Eur J Obstet Gynecol Reprod Biol 1996;70:15-17.
110. Critchley HO, Jones RL, Lea RG, et al: Role of inflammatory mediators in human endometrium during progesterone withdrawal and early pregnancy. J Clin Endocrinol Metab 1999;84:240-248.
111. Ros S, Luengo L, Feliu F, et al: Endometriosis of the small intestine as a cause of intestinal obstruction. Rev Esp Enferm Dig 1996;88:583-584.
112. Sugino N, Karube-Harada A, Kashida S, Takiguchi S, Kato H: Differential regulation of copper-zinc superoxide dismutase and manganese superoxide dismutase by progesterone withdrawal in human endometrial stromal cells. Mol Hum Reprod 2002;8:68-74.
113. Sugino N, Karube-Harada A, Kashida S, Takiguchi S, Kato H: Reactive oxygen species stimulate prostaglandin F2 α production in human endometrial stromal cells in vitro. Hum Reprod 2001;16:1797-1801.
114. Simon C, Frances A, Piquette GN, et al: Embryonic implantation in mice is blocked by interleukin-1 receptor antagonist. Endocrinology 1994;134:521-528.
115. Stewart CL: The role of leukemia inhibitory factor (LIF) and other cytokines in regulating implantation in mammals. Ann NY Acad Sci 1994;734:157-165.
116. Tabibzadeh S, Kong QF, Babaknia A, May LT: Progressive rise in the expression of interleukin-6 in human endometrium during menstrual cycle is initiated during the implantation window. Hum Reprod 1995;10:2793-2799.
117. Giudice LC: Potential biochemical markers of uterine receptivity. Hum Reprod 1999;14(suppl 2):3-16.
118. Sugino N, Karube-Harada A, Taketani T, Sakata A, Nakamura Y: Withdrawal of ovarian steroids stimulates prostaglandin F2α production through nuclear factor-κB activation via oxygen radicals in human endometrial stromal cells: potential relevance to menstruation. J Reprod Dev 2004;50:215-225.
119. Mote PA, Balleine RL, McGowan EM, Clarke CL: Colocalization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle. J Clin Endocrinol Metab 1999;84:2963-2971.
120. McKay LI, Cidlowski JA: Cross-talk between nuclear factor-κB and the steroid hormone receptors: Mechanisms of mutual antagonism. Mol Endocrinol 1998;12:45-56.
121. McKay LI, Cidlowski JA: Molecular control of immune/inflammatory responses: Interactions between nuclear factor-κB and steroid receptor-signaling pathways. Endocr Rev 1999;20:435-459.
122. Kalkhoven E, Wissink S, van der Saag PT, van der Burg B: Negative interaction between the RelA(p65) subunit of NF-κB and the progesterone receptor. J Biol Chem 1996;271:6217-6224.
123. Chen S, Wang J, Yu G, Liu W, Pearce D: Androgen and glucocorticoid receptor heterodimer formation. A possible mechanism for mutual inhibition of transcriptional activity. J Biol Chem 1997;272:14087-14092.
124. Davies S, Dai D, Feldman I, Pickett G, Leslie KK: Identification of a novel mechanism of NF-κB inactivation by progesterone through progesterone receptors in Hec50co poorly differentiated endometrial cancer cells: induction of A20 and ABIN-2. Gynecol Oncol 2004;94:463-470.
125. Gardner TS, Cantor CR, Collins JJ: Construction of a genetic toggle switch in Escherichia coli. Nature 2000;403:339-342.
126. Becskei A, Seraphin B, Serrano L: Positive feedback in eukaryotic gene networks: cell differentiation by graded to binary response conversion. Embo J 2001;20:2528-2535.
127. Ferrell JE Jr: Tripping the switch fantastic: how a protein kinase cascade can convert graded inputs into switch-like outputs. Trends Biochem Sci 1996;21:460-466.
128. de Martin R, Vanhove B, Cheng Q, et al: Cytokine-inducible expression in endothelial cells of an I κBα-like gene is regulated by NF κB. Embo J 1993;12:2773-2779.
129. Sun SC, Ganchi PA, Ballard DW, Greene WC: NF-κB controls expression of inhibitor I κB α: Evidence for an inducible autoregulatory pathway. Science 1993;259:1912-1915.
130. Ferrell JE Jr: Self-perpetuating states in signal transduction: positive feedback, double-negative feedback and bistability. Curr Opin Cell Biol 2002;14:140-148.
131. Hsieh CJ, Klump B, Holzmann K, Borchard F, Gregor M, Porschen R: Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with longstanding and extensive ulcerative colitis. Cancer Res 1998;58:3942-3945.
132. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA: Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001;61:3573-3577.
133. Song JZ, Stirzaker C, Harrison J, Melki JR, Clark SJ: Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene 2002;21:1048-1061.
134. Stirzaker C, Song JZ, Davidson B, Clark SJ: Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res 2004;64:3871-3877.
135. Wu Y, Strawn E, Basir Z, Halverson G, Guo SW: Promoter hypermethylation of progesterone receptor isoform B (PR-B) in endometriosis. Epigenetics 2006;1:106-111.
136. Vercellini P, Trecca D, Oldani S, Fracchiolla NS, Neri A, Crosignani PG: Analysis of p53 and ras gene mutations in endometriosis. Gynecol Obstet Invest 1994;38:70-71.
137. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T: Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005;11:63-70.
138. Castagnola P, Giaretti W: Mutant KRAS, chromosomal instability and prognosis in colorectal cancer. Biochim Biophys Acta 2005;1756:115-125.
139. Mayo MW, Norris JL, Baldwin AS: Ras regulation of NF-κB and apoptosis. Methods Enzymol 2001;333:73-87.
140. Kim BY, Gaynor RB, Song K, Dritschilo A, Jung M: Constitutive activation of NF-κB in Ki-ras-transformed prostate epithelial cells. Oncogene 2002;21:4490-4497.
141. Sampson J: Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol 1927;14:422-469.
142. Merrill JA: Endometrial induction of endometriosis across Millipore filters. Am J Obstet Gynecol 1966;94:780-790.
143. Kim DW, Gazourian L, Quadri SA, Romieu-Mourez R, Sherr DH, Sonenshein GE: The RelA NF-κB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells. Oncogene 2000;19:5498-5506.
144. Schenken RS, Johnson JV, Riehl RM: c-myc protooncogene polypeptide expression in endometriosis. Am J Obstet Gynecol 1991;164:1031-1036; discussion 6-7.
145. Schneider J, Jimenez E, Rodriguez F, del Tanago JG: c-myc, c-erb-B2, nm23 and p53 expression in human endometriosis. Oncol Rep 1998;5:49-52.
146. Johnson MC, Torres M, Alves A, et al: Augmented cell survival in eutopic endometrium from women with endometriosis: expression of c-myc, TGF-β1 and bax genes. Reprod Biol Endocrinol 2005;3:45.
147. Schipper JH, Frixen UH, Behrens J, Unger A, Jahnke K, Birchmeier W: E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res 1991;51(pt 1):6328-6337.
148. Andrews NA, Jones AS, Helliwell TR, Kinsella AR: Expression of the E-cadherin-catenin cell adhesion complex in primary squamous cell carcinomas of the head and neck and their nodal metastases. Br J Cancer 1997;75:1474-1480.
149. Owens DW, Brunton VG, Parkinson EK, Frame MC: E-cadherin at the cell periphery is a determinant of keratinocyte differentiation in vitro. Biochem Biophys Res Commun 2000;269:369-376.
150. Ueda M, Yamashita Y, Takehara M, et al: Gene expression of adhesion molecules and matrix metalloproteinases in endometriosis. Gynecol Endocrinol 2002;16:391-402.
151. Kuphal S, Poser I, Jobin C, Hellerbrand C, Bosserhoff AK: Loss of E-cadherin leads to upregulation of NFκB activity in malignant melanoma. Oncogene 2004;23:8509-8519.
152. Ben-Ze'ev A, Geiger B: Differential molecular interactions of β-catenin and plakoglobin in adhesion, signaling and cancer. Curr Opin Cell Biol 1998;10:629-639.
153. Conacci-Sorrell M, Zhurinsky J, Ben-Ze'ev A: The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest 2002;109:987-991.
154. Sun J, Hobert ME, Duan Y, et al: Crosstalk between NF-κB and β-catenin pathways in bacterial-colonized intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2005;289:G129-G137.
155. Lamberti C, Lin KM, Yamamoto Y, et al: Regulation of β-catenin function by the IκB kinases. J Biol Chem 2001;276:42276-42286.
156. Foyouzi N, Berkkanoglu M, Arici A, Kwintkiewicz J, Izquierdo D, Duleba AJ: Effects of oxidants and antioxidants on proliferation of endometrial stromal cells. Fertil Steril 2004;82(suppl 3):1019-1022.
157. Schreck R, Rieber P, Baeuerle PA: Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. Embo J 1991;10:2247-2258.
158. Osborn L, Kunkel S, Nabel GJ: Tumor necrosis factor α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB. Proc Natl Acad Sci USA 1989;86:2336-2340.
159. Iwabe T, Harada T, Tsudo T, et al: Tumor necrosis factor-α promotes proliferation of endometriotic stromal cells by inducing interleukin-8 gene and protein expression. J Clin Endocrinol Metab 2000;85:824-829.
160. Yang Y, Degranpre P, Kharfi A, Akoum A: Identification of macrophage migration inhibitory factor as a potent endothelial cell growth-promoting agent released by ectopic human endometrial cells. J Clin Endocrinol Metab 2000;85:4721-4727.
161. Kats R, Metz CN, Akoum A: Macrophage migration inhibitory factor is markedly expressed in active and early-stage endometriotic lesions. J Clin Endocrinol Metab 2002;87:883-889.
162. Cao WG, Morin M, Metz C, Maheux R, Akoum A: Stimulation of macrophage migration inhibitory factor expression in endometrial stromal cells by interleukin 1, β involving the nuclear transcription factor NFκB. Biol Reprod 2005;73:565-570.
163. Cao WG, Morin M, Sengers V, et al: Tumour necrosis factor-{α} up-regulates macrophage migration inhibitory factor expression in endometrial stromal cells via the nuclear transcription factor NF-{κ}B. Hum Reprod 2006;21:421-428.
164. Shakhov AN, Collart MA, Vassalli P, Nedospasov SA, Jongeneel CV: Kappa B-type enhancers are involved in lipopolysaccharidemediated transcriptional activation of the tumor necrosis factor α gene in primary macrophages. J Exp Med 1990;171:35-47.
165. Collart MA, Baeuerle P, Vassalli P: Regulation of tumor necrosis factor α transcription in macrophages: involvement of four αB-like motifs and of constitutive and inducible forms of NF-κB. Mol Cell Biol 1990;10:1498-1506.
166. Libermann TA, Baltimore D: Activation of interleukin-6 gene expression through the NF-κB transcription factor. Mol Cell Biol 1990;10:2327-2334.
167. Shimizu H, Mitomo K, Watanabe T, Okamoto S, Yamamoto K: Involvement of a NF-κB-like transcription factor in the activation of the interleukin-6 gene by inflammatory lymphokines. Mol Cell Biol 1990;10:561-568.
168. Lin YJ, Lai MD, Lei HY, Wing LY: Neutrophils and macrophages promote angiogenesis in the early stage of endometriosis in a mouse model. Endocrinology 2006;147:1278-1286.
169. Slater M, Cooper M, Murphy CR: Human growth hormone and interleukin-6 are upregulated in endometriosis and endometrioid adenocarcinoma. Acta Histochem 2006;108:13-18.
170. Mori N, Prager D: Transactivation of the interleukin-1 α promoter by human T-cell leukemia virus. Leuk Lymphoma 1997;26:421-433.
171. Khachigian LM, Resnick N, Gimbrone MA Jr, Collins T: Nuclear factor-κB interacts functionally with the platelet-derived growth factor B-chain shear-stress response element in vascular endothelial cells exposed to fluid shear stress. J Clin Invest 1995;96:1169-1175.
172. Munson L, Upadhyaya NB, Van Meter S: Platelet-derived growth factor promotes endometrial epithelial cell proliferation. Am J Obstet Gynecol 1995;173:1820-1825.
173. Laschke MW, Elitzsch A, Vollmar B, Vajkoczy P, Menger MD: Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod 2006;21:262-268.
174. Matsuzaki S, Canis M, Vaurs-Barriere C, et al: DNA microarray analysis of gene expression profiles in deep endometriosis using laser capture microdissection. Mol Hum Reprod 2004;10:719-728.
175. Duyao MP, Buckler AJ, Sonenshein GE: Interaction of an NF-κB-like factor with a site upstream of the c-myc promoter. Proc Natl Acad Sci USA 1990;87:4727-4731.
176. Watanabe H, Kanzaki H, Narukawa S, et al: Bcl-2 and Fas expression in eutopic and ectopic human endometrium during the menstrual cycle in relation to endometrial cell apoptosis. Am J Obstet Gynecol 1997;176:360-368.
177. Jones RK, Searle RF, Bulmer JN: Apoptosis and bcl-2 expression in normal human endometrium, endometriosis and adenomyosis. Hum Reprod 1998;13:3496-3502.
178. Goumenou A, Panayiotides I, Matalliotakis I, Vlachonikolis I, Tzardi M, Koumantakis E: Bcl-2 and Bax expression in human endometriotic and adenomyotic tissues. Eur J Obstet Gynecol Reprod Biol 2001;99:256-260.
179. Nezhat FR, Kalir T: Comparative immunohistochemical studies of endometriosis lesions and endometriotic cysts. Fertil Steril 2002;78:820-824.
180. Goumenou AG, Matalliotakis IM, Tzardi M, Fragouli YG, Mahutte NG, Arici A: Apoptosis and differential expression of apoptosis-related proteins in endometriotic glandular and stromal cells. J Soc Gynecol Investig 2004;11:318-322.
181. Ueda M, Yamashita Y, Takehara M, et al: Survivin gene expression in endometriosis. J Clin Endocrinol Metab 2002;87:3452-3459.
182. Goteri G, Lucarini G, Pieramici T, et al: Endothelial cell survivin is involved in the growth of ovarian endometriotic cysts. Anticancer Res 2005;25:4313-4318.
183. Catz SD, Johnson JL: Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer. Oncogene 2001;20:7342-7351.
184. Zhu L, Fukuda S, Cordis G, Das DK, Maulik N: Anti-apoptotic protein survivin plays a significant role in tubular morphogenesis of human coronary arteriolar endothelial cells by hypoxic preconditioning. FEBS Lett 2001;508:369-374.
185. Gaetje R, Kotzian S, Herrmann G, Baumann R, Starzinski-Powitz A: Invasiveness of endometriotic cells in vitro. Lancet 1995;346:1463-1464.
186. Malik RK, Parsons JT: Integrin-mediated signaling in normal and malignant cells: a role of protein tyrosine kinases. Biochim Biophys Acta 1996;1287:73-76.
187. Ossowski L: Invasion of connective tissue by human carcinoma cell lines: Requirement for urokinase, urokinase receptor, and interstitial collagenase. Cancer Res 1992;52:6754-6760.
188. Seynaeve CM, Stetler-Stevenson M, Sebers S, Kaur G, Sausville EA, Worland PJ: Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 1993;53:2081-2086.
189. Ossowski L, Reich E: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983;35(pt 2):611-619.
190. Ossowski L: In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol 1988;107(pt 1):2437-2445.
191. Matrisian LM: The matrix-degrading metalloproteinases. Bioessays 1992;14:455-463.
192. Bar-Eli M: Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 1999;67:12-18.
193. Fernandez-Shaw S, Marshall JM, Hicks B, Barlow DH, Starkey PM: Plasminogen activators in ectopic and uterine endometrium. Fertil Steril 1995;63:45-51.
194. Bruse C, Bergqvist A, Carlstrom K, Fianu-Jonasson A, Lecander I, Astedt B: Fibrinolytic factors in endometriotic tissue, endometrium, peritoneal fluid, and plasma from women with endometriosis and in endometrium and peritoneal fluid from healthy women. Fertil Steril 1998;70:821-826.
195. Guan YM, Carlberg M, Bruse C, Carlstrom K, Bergqvist A: Effects of hormones on uPA, PAI-1 and suPAR from cultured endometrial and ovarian endometriotic stromal cells. Acta Obstet Gynecol Scand 2002;81:389-397.
196. Kobayashi H: Invasive capacity of heterotopic endometrium. Gynecol Obstet Invest 2000;50(suppl 1):26-32.
197. Gilabert-Estelles J, Estelles A, Gilabert J, et al: Expression of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis. Hum Reprod 2003;18:1516-1522.
198. Bruse C, Radu D, Bergqvist A: In situ localization of mRNA for the fibrinolytic factors uPA, PAI-1 and uPAR in endometriotic and endometrial tissue. Mol Hum Reprod 2004;10:159-166.
199. Bruse C, Guan Y, Carlberg M, Carlstrom K, Bergqvist A: Basal release of urokinase plasminogen activator, plasminogen activator inhibitor-1, and soluble plasminogen activator receptor from separated and cultured endometriotic and endometrial stromal and epithelial cells. Fertil Steril 2005;83(suppl 1):1155-1160.
200. Sillem M, Prifti S, Neher M, Runnebaum B: Extracellular matrix remodelling in the endometrium and its possible relevance to the pathogenesis of endometriosis. Hum Reprod Update 1998;4:730-735.
201. Edelstam G, Lecander I, Larsson B, Astedt B: Fibrinolysis in the peritoneal fluid during adhesions, endometriosis and ongoing pelvic inflammatory disease. Inflammation 1998;22:341-351.
202. Ramon L, Gilabert-Estelles J, Castello R, et al: mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay. Hum Reprod 2005;20:272-278.
203. Osteen KG, Yeaman GR, Bruner-Tran KL: Matrix metalloproteinases and endometriosis. Semin Reprod Med 2003;21:155-164.
204. Zhou HE, Nothnick WB: The relevancy of the matrix metalloproteinase system to the pathophysiology of endometriosis. Front Biosci 2005;10:569-575.
205. Chung HW, Wen Y, Chun SH, Nezhat C, Woo BH, Lake Polan M: Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-3 mRNA expression in ectopic and eutopic endometrium in women with endometriosis: a rationale for endometriotic invasiveness. Fertil Steril 2001;75:152-159.
206. Liu XJ, He YL, Peng DX: Expression of metalloproteinase-9 in ectopic endometrium in women with endometriosis. Di Yi Jun Yi Da Xue Xue Bao 2002;22:467-469.
207. Collette T, Bellehumeur C, Kats R, et al: Evidence for an increased release of proteolytic activity by the eutopic endometrial tissue in women with endometriosis and for involvement of matrix metalloproteinase-9. Hum Reprod 2004;19:1257-1264.
208. Akoum A, Lawson C, McColl S, Villeneuve M: Ectopic endometrial cells express high concentrations of interleukin (IL)-8 in vivo regardless of the menstrual cycle phase and respond to oestradiol by up-regulating IL-1-induced IL-8 expression in vitro. Mol Hum Reprod 2001;7:859-866.
209. Darai E, Detchev R, Hugol D, Quang NT: Serum and cyst fluid levels of interleukin (IL)-6, IL-8 and tumour necrosis factor-α in women with endometriomas and benign and malignant cystic ovarian tumours. Hum Reprod 2003;18:1681-1685.
210. Mulayim N, Savlu A, Guzeloglu-Kayisli O, Kayisli UA, Arici A: Regulation of endometrial stromal cell matrix metalloproteinase activity and invasiveness by interleukin-8. Fertil Steril 2004;81(suppl 1):904-911.
211. Bond M, Fabunmi RP, Baker AH, Newby AC: Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-κB. FEBS Lett 1998;435:29-34.
212. Bond M, Baker AH, Newby AC: Nuclear factor κB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun 1999;264:561-567.
213. Farina AR, Tacconelli A, Vacca A, Maroder M, Gulino A, Mackay AR: Transcriptional up-regulation of matrix metalloproteinase-9 expression during spontaneous epithelial to neuroblast phenotype conversion by SKN-SH neuroblastoma cells, involved in enhanced invasivity, depends upon GT-box and nuclear factor κB elements. Cell Growth Differ 1999;10:353-367.
214. Yan C, Wang H, Aggarwal B, Boyd DD: A novel homologous recombination system to study 92 kDa type IV collagenase transcription demonstrates that the NF-κB motif drives the transition from a repressed to an activated state of gene expression. FASEB J 2004;18:540-541.
215. Novak U, Cocks BG, Hamilton JA: A labile repressor acts through the NFkappaB-like binding sites of the human urokinase gene. Nucleic Acids Res 1991;19:3389-3393.
216. Kunsch C, Rosen CA: NF-κB subunit-specific regulation of the interleukin-8 promoter. Mol Cell Biol 1993;13:6137-6146.
217. Wang W, Abbruzzese JL, Evans DB, Chiao PJ: Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene 1999;18:4554-4563.
218. Sakamoto Y, Harada T, Horie S, et al: Tumor necrosis factor-α- induced interleukin-8 (IL-8) expression in endometriotic stromal cells, probably through nuclear factor-κB activation: gonadotropin-releasing hormone agonist treatment reduced IL-8 expression. J Clin Endocrinol Metab 2003;88:730-735.
219. Horie S, Harada T, Mitsunari M, Taniguchi F, Iwabe T, Terakawa N: Progesterone and progestational compounds attenuate tumor necrosis factor α-induced interleukin-8 production via nuclear factor κB inactivation in endometriotic stromal cells. Fertil Steril 2005;83:1530-1535.
220. Sliva D, English D, Lyons D, Lloyd FP Jr: Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-κB. Biochem Biophys Res Commun 2002;290:552-557.
221. Mahabeleshwar GH, Kundu GC: Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor κB-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3′-kinase activity in breast cancer cells. J Biol Chem 2003;278:6209-6221.
222. Igarashi TM, Bruner-Tran KL, Yeaman GR, et al: Reduced expression of progesterone receptor-B in the endometrium of women with endometriosis and in cocultures of endometrial cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Fertil Steril 2005;84:67-74.
223. Ueda A, Kawamoto S, Igarashi T, et al: Human monocyte chemoattractant protein-1 expressed in a baculovirus system. Gene 1994;140:267-272.
224. Ueda A, Ishigatsubo Y, Okubo T, Yoshimura T: Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF-κB sites and NF-κB/Rel subunit specificity. J Biol Chem 1997;272:31092-31099.
225. Chilov D, Kukk E, Taira S, et al: Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem 1997;272:25176-25183.
226. Levine L, Lucci JA 3rd, Pazdrak B, et al: Bombesin stimulates nuclear factor κB activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 2003;63:3495-3502.
227. Gao Y, Luo L, He F: Effect of IL-1 β and TNF-α on the expression of monocyte chemotactic protein-1 in endometriotic cells. J Tongji Med Univ 1999;19:212-214.
228. Donnez J, Smoes P, Gillerot S, Casanas-Roux F, Nisolle M: Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod 1998;13:1686-1690.
229. Kupker W, Schultze-Mosgau A, Diedrich K: Paracrine changes in the peritoneal environment of women with endometriosis. Hum Reprod Update 1998;4:719-723.
230. Fasciani A, D'Ambrogio G, Bocci G, Monti M, Genazzani AR, Artini PG: High concentrations of the vascular endothelial growth factor and interleukin-8 in ovarian endometriomata. Mol Hum Reprod 2000;6:50-54.
231. Mahnke JL, Dawood MY, Huang JC: Vascular endothelial growth factor and interleukin-6 in peritoneal fluid of women with endometriosis. Fertil Steril 2000;73:166-170.
232. Tan XJ, Lang JH, Liu DY, Shen K, Leng JH, Zhu L: Expression of vascular endothelial growth factor and thrombospondin-1 mRNA in patients with endometriosis. Fertil Steril 2002;78:148-153.
233. Wu MH, Yang BC, Lee YC, Wu PL, Hsu CC: The differential expression of intercellular adhesion molecule-1 (ICAM-1) and regulation by interferon-γ during the pathogenesis of endometriosis. Am J Reprod Immunol 2004;51:373-380.
234. Vigano P, Gaffuri B, Somigliana E, Busacca M, Di Blasio AM, Vignali M: Expression of intercellular adhesion molecule (ICAM)-1 mRNA and protein is enhanced in endometriosis versus endometrial stromal cells in culture. Mol Hum Reprod 1998;4:1150-1156.
235. Skrzypczak J, Szczepanska M, Puk E, Kamieniczna M, Kurpisz M: Peritoneal fluid cytokines and sICAM-1 in minimal endometriosis: search for discriminating factors between infertility and/or endometriosis. Eur J Obstet Gynecol Reprod Biol 2005;122:95-103.
236. Fukaya T, Sugawara J, Yoshida H, Murakami T, Yajima A: Intercellular adhesion molecule-1 and hepatocyte growth factor in human endometriosis: Original investigation and a review of literature. Gynecol Obstet Invest 1999;47(suppl 1):11-16; discussion 6-7.
237. Calhaz-Jorge C, Costa AP, Santos MC, Palma-Carlos ML: Soluble intercellular adhesion molecule 1 in the peritoneal fluid of patients with endometriosis correlates with the extension of peritoneal implants. Eur J Obstet Gynecol Reprod Biol 2003;106:170-174.
238. Barrier BF, Sharpe-Timms KL: Expression of soluble adhesion molecules in sera of women with stage III and IV endometriosis. J Soc Gynecol Investig 2002;9:98-101.
239. Wu MH, Yang BC, Hsu CC, Lee YC, Huang KE: The expression of soluble intercellular adhesion molecule-1 in endometriosis. Fertil Steril 1998;70:1139-1142.
240. De Placido G, Alviggi C, Di Palma G, et al: Serum concentrations of soluble human leukocyte class I antigens and of the soluble intercellular adhesion molecule-1 in endometriosis: relationship with stage and non-pigmented peritoneal lesions. Hum Reprod 1998;13:3206-3210.
241. Leng J, Lang J, Zhao D, Liu D: Serum levels of soluble intercellular molecule 1 (sICAM-1) in endometriosis. Zhonghua Yi Xue Za Zhi 2002;82:189-190.
242. Daniel Y, Geva E, Amit A, et al: Do soluble cell adhesion molecules play a role in endometriosis? Am J Reprod Immunol 2000;43:160-166.
243. Matalliotakis IM, Vassiliadis S, Goumenou AG, et al: Soluble ICAM-1 levels in the serum of endometriotic patients appear to be independent of medical treatment. J Reprod Immunol 2001;51:9-19.
244. Somigliana E, Vigano P, Candiani M, Felicetta I, Di Blasio AM, Vignali M: Use of serum-soluble intercellular adhesion molecule-1 as a new marker of endometriosis. Fertil Steril 2002;77:1028-1031.
245. Steff AM, Gagne D, Page M, Hugo P, Gosselin D: Concentration of soluble intercellular adhesion molecule-1 in serum samples from patients with endometriosis collected during the luteal phase of the menstrual cycle. Hum Reprod 2004;19:172-178.
246. Ueda A, Okuda K, Ohno S, et al: NF-κB and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol 1994;153:2052-2063.
247. van de Stolpe A, Caldenhoven E, Stade BG, et al: 12-O- tetradecanoylphorbol-13-acetate-and tumor necrosis factor α-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter. J Biol Chem 1994;269:6185-6192.
248. Barnes PJ, Karin M: Nuclear factor-κB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071.
249. Wu MY, Ho HN, Chen SU, Chao KH, Chen CD, Yang YS: Increase in the production of interleukin-6, interleukin-10, and interleukin-12 by lipopolysaccharide-stimulated peritoneal macrophages from women with endometriosis. Am J Reprod Immunol 1999;41:106-111.
250. Keenan JA, Chen TT, Chadwell NL, Torry DS, Caudle MR: IL-1 β, TNF-α, and IL-2 in peritoneal fluid and macrophage-conditioned media of women with endometriosis. Am J Reprod Immunol 1995;34:381-385.
251. Harada T, Yoshioka H, Yoshida S, et al: Increased interleukin-6 levels in peritoneal fluid of infertile patients with active endometriosis. Am J Obstet Gynecol 1997;176:593-597.
252. Harada T, Enatsu A, Mitsunari M, et al: Role of cytokines in progression of endometriosis. Gynecol Obstet Invest 1999;47(suppl 1):34-39; discussion 9-40.
253. Thompson HE, Holmes JH, Gottesfeld KR, Taylor ES: Ultrasound as a diagnostic aid in diseases of the pelvis. Am J Obstet Gynecol 1967;98:472-481.
254. Hornung D, Bentzien F, Wallwiener D, Kiesel L, Taylor RN: Chemokine bioactivity of RANTES in endometriotic and normal endometrial stromal cells and peritoneal fluid. Mol Hum Reprod 2001;7:163-168.
255. Lebovic DI, Chao VA, Martini JF, Taylor RN: IL-1β induction of RANTES (regulated upon activation, normal T cell expressed and secreted) chemokine gene expression in endometriotic stromal cells depends on a nuclear factor-κB site in the proximal promoter. J Clin Endocrinol Metab 2001;86:4759-4764.
256. Lin YJ, Lai MD, Lei HY, Wing LY: Neutrophils and macrophages promote angiogenesis in the early stage of endometriosis in a mouse model. Endocrinology 2006;147:1278-1286.
257. Pizzo A, Salmeri FM, Ardita FV, Sofo V, Tripepi M, Marsico S: Behaviour of cytokine levels in serum and peritoneal fluid of women with endometriosis. Gynecol Obstet Invest 2002;54:82-87.
258. Akoum A, Lemay A, Brunet C, Hebert J: Secretion of monocyte chemotactic protein-1 by cytokine-stimulated endometrial cells of women with endometriosis. Le groupe d'investigation en gynecologie. Fertil Steril 1995;63:322-328.
259. Tartaglia LA, Goeddel DV: Two TNF receptors. Immunol Today 1992;13:151-153.
260. Dempsey PW, Doyle SE, He JQ, Cheng G: The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003;14:193-209.
261. Wajant H, Pfizenmaier K, Scheurich P: Tumor necrosis factor signaling. Cell Death Differ 2003;10:45-65.
262. Chen G, Goeddel DV: TNF-R1 signaling: a beautiful pathway. Science 2002;296:1634-1635.
263. Chen G, Cao P, Goeddel DV: TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol Cell 2002;9:401-410.
264. Rothe M, Sarma V, Dixit VM, Goeddel DV: TRAF2-mediated activation of NF-κB by TNF receptor 2 and CD40. Science 1995;269:1424-1427.
265. Ashkenazi A, Dixit VM: Death receptors: signaling and modulation. Science 1998;281:1305-1308.
266. Braun DP, Ding J, Dmowski WP: Peritoneal fluid-mediated enhancement of eutopic and ectopic endometrial cell proliferation is dependent on tumor necrosis factor-α in women with endometriosis. Fertil Steril 2002;78:727-732.
267. Shaulian E, Karin M: AP-1 as a regulator of cell life and death. Nat Cell Biol 2002;4:E131-E136.
268. Shaulian E, Karin M: AP-1 in cell proliferation and survival. Oncogene 2001;20:2390-2400.
269. Fan W, Yanase T, Morinaga H, et al: Activation of peroxisome proliferator-activated receptor-γ and retinoid X receptor inhibits aromatase transcription via nuclear factor-κB. Endocrinology 2005;146:85-92.
270. Ghosh S, Wu Y, Li R, Hu Y: Jun proteins modulate the ovary-specific promoter of aromatase gene in ovarian granulosa cells via a cAMP-responsive element. Oncogene 2005;24:2236-2246.
271. Nishida M, Nasu K, Fukuda J, Kawano Y, Narahara H, Miyakawa I: Down-regulation of interleukin-1 receptor type 1 expression causes the dysregulated expression of CXC chemokines in endometriotic stromal cells: a possible mechanism for the altered immunological functions in endometriosis. J Clin Endocrinol Metab 2004;89:5094-5100.
272. Gupta S, Gollapudi S: Molecular mechanisms of TNF-α-induced apoptosis in aging human T cell subsets. Int J Biochem Cell Biol 2005;37:1034-1042.
273. Rojas-Cartagena C, Appleyard CB, Santiago OI, Flores I: Experimental intestinal endometriosis is characterized by increased levels of soluble TNFRSF1B and downregulation of Tnfrsf1a and Tnfrsf1b gene expression. Biol Reprod 2005;73:1211-1218.
274. D'Antonio M, Martelli F, Peano S, Papoian R, Borrelli F: Ability of recombinant human TNF binding protein-1 (r-hTBP-1) to inhibit the development of experimentallyinduced endometriosis in rats. J Reprod Immunol 2000;48:81-98.
275. D'Hooghe TM, Nugent NP, Cuneo S, et al: Recombinant human TNFRSF1A (rhTBP1) inhibits the development of endometriosis in baboons: A prospective, randomized, placebo- and drug-controlled study. Biol Reprod 2006;74:131-136.
276. Kast RE: Evidence of a mechanism by which etanercept increased TNF-α in multiple myeloma: new insights into the biology of TNF-α giving new treatment opportunities - the role of bupropion. Leuk Res 2005;29:1459-1463.
277. Yamamoto K, Arakawa T, Ueda N, Yamamoto S: Transcriptional roles of nuclear factor κB and nuclear factor-interleukin-6 in the tumor necrosis factor α-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 1995;270:31315-31320.
278. Smith WL, Garavito RM, DeWitt DL: Prostaglandin endoperoxide H synthases (cyclooxygenases)- 1 and -2. J Biol Chem 1996;271:33157-33160.
279. Herschman HR: Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev 1994;13:241-256.
280. Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
281. Ota H, Igarashi S, Sasaki M, Tanaka T: Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod 2001;16:561-566.
282. Matsuzaki S, Canis M, Pouly JL, Wattiez A, Okamura K, Mage G: Cyclooxygenase-2 expression in deep endometriosis and matched eutopic endometrium. Fertil Steril 2004;82:1309-1315.
283. Dogan E, Saygili U, Posaci C, et al: Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib. Fertil Steril 2004;82(suppl 3):1115-1120.
284. Matsuzaki S, Canis M, Darcha C, Dallel R, Okamura K, Mage G: Cyclooxygenase-2 selective inhibitor prevents implantation of eutopic endometrium to ectopic sites in rats. Fertil Steril 2004;82:1609-1615.
285. Sahu SC: Oncogenes, oncogenesis, and oxygen radicals. Biomed Environ Sci 1990;3:183-201.
286. Floyd RA: Oxidative damage to behavior during aging. Science 1991;254:1597.
287. Klein JA, Ackerman SL: Oxidative stress, cell cycle, and neurodegeneration. J Clin Invest 2003;111:785-793.
288. Fridovich I: Fundamental aspects of reactive oxygen species, or what's the matter with oxygen? Ann NY Acad Sci 1999;893:13-18.
289. Zelko IN, Mariani TJ, Folz RJ: Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med 2002;33:337-349.
290. Arumugam K, Dip YC: Endometriosis and infertility: the role of exogenous lipid peroxides in the peritoneal fluid. Fertil Steril 1995;63:198-199.
291. Ho HN, Wu MY, Chen SU, Chao KH, Chen CD, Yang YS: Total antioxidant status and nitric oxide do not increase in peritoneal fluids from women with endometriosis. Hum Reprod 1997;12:2810-2815.
292. Wang Y, Sharma RK, Falcone T, Goldberg J, Agarwal A: Importance of reactive oxygen species in the peritoneal fluid of women with endometriosis or idiopathic infertility. Fertil Steril 1997;68:826-830.
293. Murphy AA, Palinski W, Rankin S, Morales AJ, Parthasarathy S: Evidence for oxidatively modified lipid-protein complexes in endometrium and endometriosis. Fertil Steril 1998;69:1092-1094.
294. Murphy AA, Palinski W, Rankin S, Morales AJ, Parthasarathy S: Macrophage scavenger receptor(s) and oxidatively modified proteins in endometriosis. Fertil Steril 1998;69:1085-1091.
295. Shanti A, Santanam N, Morales AJ, Parthasarathy S, Murphy AA: Autoantibodies to markers of oxidative stress are elevated in women with endometriosis. Fertil Steril 1999;71:1115-1118.
296. Rong R, Ramachandran S, Santanam N, Murphy AA, Parthasarathy S: Induction of monocyte chemotactic protein-1 in peritoneal mesothelial and endometrial cells by oxidized low-density lipoprotein and peritoneal fluid from women with endometriosis. Fertil Steril 2002;78:843-848.
297. Szczepanska M, Kozlik J, Skrzypczak J, Mikolajczyk M: Oxidative stress may be a piece in the endometriosis puzzle. Fertil Steril 2003;79:1288-1293.
298. Ota H, Igarashi S, Kato N, Tanaka T: Aberrant expression of glutathione peroxidase in eutopic and ectopic endometrium in endometriosis and adenomyosis. Fertil Steril 2000;74:313-318.
299. Ishikawa M, Nakata T, Yaginuma Y, Nishiwaki K, Goishi K, Saitoh S: Expression of superoxide dismutase (SOD) in adenomyosis. Am J Obstet Gynecol 1993;169:730-734.
300. Ota H, Igarashi S, Hatazawa J, Tanaka T: Immunohistochemical assessment of superoxide dismutase expression in the endometrium in endometriosis and adenomyosis. Fertil Steril 1999;72:129-134.
301. Li YQ, Zhang ZX, Xu YJ, et al: N-Acetyl-Lcysteine and pyrrolidine dithiocarbamate inhibited nuclear factor-κB activation in alveolar macrophages by different mechanisms. Acta Pharmacol Sin 2006;27:339-346.
302. Li N, Karin M: Is NF-κB the sensor of oxidative stress? FASEB J 1999;13:1137-1143.
303. Hehner SP, Breitkreutz R, Shubinsky G, et al: Enhancement of T cell receptor signaling by a mild oxidative shift in the intracellular thiol pool. J Immunol 2000;165:4319-4328.
304. Haddad EB, Salmon M, Koto H, Barnes PJ, Adcock I, Chung KF: Ozone induction of cytokine-induced neutrophil chemoattractant (CINC) and nuclear factor-κb in rat lung: inhibition by corticosteroids. FEBS Lett 1996;379:265-268.
305. Rupec RA, Baeuerle PA: The genomic response of tumor cells to hypoxia and reoxygenation. Differential activation of transcription factors AP-1 and NF-κB. Eur J Biochem 1995;234:632-640.
306. Das KC, Lewis-Molock Y, White CW: Activation of NF-κB and elevation of MnSOD gene expression by thiol reducing agents in lung adenocarcinoma (A549) cells. Am J Physiol 1995;269(pt 1):L588-L602.
307. Rojo AI, Salinas M, Martin D, Perona R, Cuadrado A: Regulation of Cu/Zn-superoxide dismutase expression via the phosphatidylinositol 3 kinase/Akt pathway and nuclear factor-κB. J Neurosci 2004;24:7324-7334.
308. Xie QW, Kashiwabara Y, Nathan C: Role of transcription factor NF-κB/Rel in induction of nitric oxide synthase. J Biol Chem 1994;269:4705-4708.
309. Taylor BS, de Vera ME, Ganster RW, et al: Multiple NF-κB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. J Biol Chem 1998;273:15148-15156.
310. Nathan C: Nitric oxide as a secretory product of mammalian cells. FASEB J 1992;6:3051-3064.
311. Nussler AK, Billiar TR: Inflammation, immunoregulation, and inducible nitric oxide synthase. J Leukoc Biol 1993;54:171-178.
312. McCartney-Francis N, Allen JB, Mizel DE, et al: Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med 1993;178:749-754.
313. Koprowski H, Zheng YM, Heber-Katz E, et al: In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. Proc Natl Acad Sci USA 1993;90:3024-3027.
314. Middleton SJ, Shorthouse M, Hunter JO: Increased nitric oxide synthesis in ulcerative colitis. Lancet 1993;341:465-466.
315. Hierholzer C, Harbrecht B, Menezes JM, et al: Essential role of induced nitric oxide in the initiation of the inflammatory response after hemorrhagic shock. J Exp Med 1998;187:917-928.
316. Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G: Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci USA 1992;89:11259-11263.
317. Mannick JB, Asano K, Izumi K, Kieff E, Stamler JS: Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell 1994;79:1137-1146.
318. Granger DL, Hibbs JB Jr, Perfect JR, Durack DT: Specific amino acid (L-arginine) requirement for the microbiostatic activity of murine macrophages. J Clin Invest 1988;81:1129-1136.
319. Saavedra JE, Billiar TR, Williams DL, Kim YM, Watkins SC, Keefer LK: Targeting nitric oxide (NO) delivery in vivo. Design of a liver-selective NO donor prodrug that blocks tumor necrosis factor-α-induced apoptosis and toxicity in the liver. J Med Chem 1997;40:1947-1954.
320. Stuehr DJ, Nathan CF: Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 1989;169:1543-1555.
321. Harbrecht BG, Wu B, Watkins SC, Marshall HP Jr, Peitzman AB, Billiar TR: Inhibition of nitric oxide synthase during hemorrhagic shock increases hepatic injury. Shock 1995;4:332-337.
322. Hatazawa J, Ota H, Murata M, Igarashi S, Tanaka T: Localization of endothelial nitric oxide synthase messenger ribonucleic acid by in situ hybridization in ectopic endometrial tissue in patients with adenomyosis. Reprod Fertil Dev 2000;12:283-287.
323. Osborn BH, Haney AF, Misukonis MA, Weinberg JB: Inducible nitric oxide synthase expression by peritoneal macrophages in endometriosis-associated infertility. Fertil Steril 2002;77:46-51.
324. Ota H, Igarashi S, Hatazawa J, Tanaka T: Endothelial nitric oxide synthase in the endometrium during the menstrual cycle in patients with endometriosis and adenomyosis. Fertil Steril 1998;69:303-308.
325. Wu MY, Chao KH, Yang JH, Lee TH, Yang YS, Ho HN: Nitric oxide synthesis is increased in the endometrial tissue of women with endometriosis. Hum Reprod 2003;18:2668-2671.
326. Khorram O, Lessey BA: Alterations in expression of endometrial endothelial nitric oxide synthase and α(v)β(3) integrin in women with endometriosis. Fertil Steril 2002;78:860-864.
327. Wang J, Zhou F, Dong M, Wu R, Qian Y: Prolonged gonadotropin-releasing hormone agonist therapy reduced expression of nitric oxide synthase in the endometrium of women with endometriosis and infertility. Fertil Steril 2006;85:1037-1044.
328. Murphy AA, Santanam N, Parthasarathy S: Endometriosis: a disease of oxidative stress? Semin Reprod Endocrinol 1998;16:263-273.
329. Palvimo JJ, Reinikainen P, Ikonen T, Kallio PJ, Moilanen A, Janne OA: Mutual transcriptional interference between RelA and androgen receptor. J Biol Chem 1996;271:24151-24156.
330. Kawasaki H, Taira K: Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature 2004;431:211-217.
331. Morris KV, Chan SW, Jacobsen SE, Looney DJ: Small interfering RNA-induced transcriptional gene silencing in human cells. Science 2004;305:1289-1292.
332. Tufarelli C, Stanley JA, Garrick D, et al: Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease. Nat Genet 2003;34:157-165.
333. Hastings JM, Jackson KS, Mavrogianis PA, Fazleabas AT: The estrogen early response gene, FOS, is altered in a baboon model of endometriosis. Biol Reprod 2006;75:176-182.
334. Bakin AV, Curran T: Role of DNA 5-methylcytosine transferase in cell transformation by fos. Science 1999;283:387-390.
335. Guo S, Wu Y, Strawn E, Basir Z, Halverson G: Aberrant expression of DNA methyltransferases DNMT1 and DNMT3B in endometriosis. Fertil Steril 2005;84(suppl 1):S125.
336. Zhang N, Oppenheim JJ: Crosstalk between chemokines and neuronal receptors bridges immune and nervous systems. J Leukoc Biol 2005;78:1210-1214.
337. Zhang N, Rogers TJ, Caterina M, Oppenheim JJ: Proinflammatory chemokines, such as C-C chemokine ligand 3, desensitize mu-opioid receptors on dorsal root ganglia neurons. J Immunol 2004;173:594-599.
338. Zhang N, Inan S, Cowan A, et al: A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicin-gated ion channel TRPV1. Proc Natl Acad Sci USA 2005;102:4536-4541.
339. Szabo I, Wetzel M, McCarthy L, et al: Interactions of opioid receptors, chemokines, and chemokine receptors. Adv Exp Med Biol 2001;493:69-74.
340. Szabo I, Chen XH, Xin L, et al: Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain. Proc Natl Acad Sci USA 2002;99:10276-10281.
341. Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S: Cytokines, nerve growth factor and inflammatory hyperalgesia: The contribution of tumour necrosis factor α. Br J Pharmacol 1997;121:417-424.
342. Junger H, Sorkin LS: Nociceptive and inflammatory effects of subcutaneous TNFα. Pain 2000;85:145-151.
343. Joseph EK, Levine JD: Caspase signalling in neuropathic and inflammatory pain in the rat. Eur J Neurosci 2004;20:2896-2902.
344. Sommer C, Kress M: Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 2004;361:184-187.
345. Kaneuchi M, Sasaki M, Tanaka Y, et al: WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer 2005;104:1924-1930.
346. Murphy AA, Zhou MH, Malkapuram S, Santanam N, Parthasarathy S, Sidell N: RU486-induced growth inhibition of human endometrial cells. Fertil Steril 2000;74:1014-1019.
347. Han S, Sidell N: RU486-induced growth inhibition of human endometrial cells involves the nuclear factor-κB signaling pathway. J Clin Endocrinol Metab 2003;88:713-719.
348. Wu Y, Guo SW: Inhibition of proliferation of endometrial stromal cells by trichostatin A, RU486, CDB-2914, N-acetylcysteine, and ICI 182780. Gynecol Obstet Invest 2006;62:193-205.
349. Kettel LM, Murphy AA, Morales AJ, Ulmann A, Baulieu EE, Yen SS: Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 1996;65:23-28.
350. Kettel LM, Murphy AA, Morales AJ, Yen SS: Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol 1998;178:1151-1156.
351. Slayden OD, Brenner RM: Hormonal regulation and localization of estrogen, progestin and androgen receptors in the endometrium of nonhuman primates: effects of progesterone receptor antagonists. Arch Histol Cytol 2004;67:393-409.
352. Beck CA, Weigel NL, Moyer ML, Nordeen SK, Edwards DP: The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc Natl Acad Sci USA 1993;90:4441-4445.
353. Ray A, Prefontaine KE: Physical association and functional antagonism between the p65 subunit of transcription factor NF-κB and the glucocorticoid receptor. Proc Natl Acad Sci USA 1994;91:752-756.
354. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS Jr: Characterization of mechanisms involved in transrepression of NF-κB by
355. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr: Role of transcriptional activation of I κBα in mediation of immunosuppression by glucocorticoids. Science 1995;270:283-286.
356. Nelson G, Wilde GJ, Spiller DG, et al: NF-κB signalling is inhibited by glucocorticoid receptor and STAT6 via distinct mechanisms. J Cell Sci 2003;116(pt 12):2495-2503.
357. Garside H, Stevens A, Farrow S, et al: Glucocorticoid ligands specify different interactions with NF-κB by allosteric effects on the glucocorticoid receptor DNA binding domain. J Biol Chem 2004;279:50050-50059.
358. Yagyu T, Kobayashi H, Matsuzaki H, et al: Thalidomide inhibits tumor necrosis factor-α-induced interleukin-8 expression in endometriotic stromal cells, possibly through suppression of nuclear factor-κB activation. J Clin Endocrinol Metab 2005;90:3017-3021.
359. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr: Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity. J Biol Chem 2001;276:22382-22387.
360. Wieser F, Vigne JL, Ryan I, Hornung D, Djalali S, Taylor RN: Sulindac suppresses nuclear factor-κB activation and RANTES gene and protein expression in endometrial stromal cells from women with endometriosis. J Clin Endocrinol Metab 2005;90:6441-6447.
361. Yin MJ, Yamamoto Y, Gaynor RB: The antiinflammatory agents aspirin and salicylate inhibit the activity of I(κ)B kinase-β. Nature 1998;396:77-80.
362. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB: Sulindac inhibits activation of the NF-κB pathway. J Biol Chem 1999;274:27307-27314.
363. Pinkus R, Weiner LM, Daniel V: Role of oxidants and antioxidants in the induction of AP-1, NF-κB, and glutathione S-transferase gene expression. J Biol Chem 1996;271:13422-13429.
364. Caccamo D, Campisi A, Marini H, et al: Glutamate promotes NF-κB pathway in primary astrocytes: protective effects of IRFI 016, a synthetic vitamin E analogue. Exp Neurol 2005;193:377-383.
365. Pritts EA, Zhao D, Ricke E, Waite L, Taylor RN: PPAR-γ decreases endometrial stromal cell transcription and translation of RANTES in vitro. J Clin Endocrinol Metab 2002;87:1841-1844.
366. Pritts EA, Zhao D, Sohn SH, Chao VA, Waite LL, Taylor RN: Peroxisome proliferator-activated receptor-γ ligand inhibition of RANTES production by human endometriotic stromal cells is mediated through an upstream promoter element. Fertil Steril 2003;80:415-420.
367. Lebovic DI, Kir M, Casey CL: Peroxisome proliferator-activated receptor-γ induces regression of endometrial explants in a rat model of endometriosis. Fertil Steril 2004;82(suppl 3):1008-1013.
368. Demirturk F, Aytan H, Caliskan AC, Aytan P, Koseoglu DR: Effect of peroxisome proliferator-activated receptor-γ agonist rosiglitazone on the induction of endometriosis in an experimental rat model. J Soc Gynecol Investig 2006;13:58-62.
369. Liu D, Zeng BX, Zhang SH, Yao SL: Rosiglitazone, an agonist of peroxisome proliferator-activated receptor γ, reduces pulmonary inflammatory response in a rat model of endotoxemia. Inflamm Res 2005;54:464-470.
370. Collino M, Aragno M, Mastrocola R, et al: Modulation of the oxidative stress and inflammatory response by PPAR-γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 2006;530:70-80.
371. Harris HA, Bruner-Tran KL, Zhang X, Osteen KG, Lyttle CR: A selective estrogen receptor-β agonist causes lesion regression in an experimentally induced model of endometriosis. Hum Reprod 2005;20:936-941.
372. Valentine JE, Kalkhoven E, White R, Hoare S, Parker MG: Mutations in the estrogen receptor ligand binding domain discriminate between hormone-dependent transactivation and transrepression. J Biol Chem 2000;275:25322-25329.
373. Tyree CM, Zou A, Allegretto EA: 17β-Estradiol inhibits cytokine induction of the human E-selectin promoter. J Steroid Biochem Mol Biol 2002;80:291-297.
374. Pelzer T, Neumann M, de Jager T, Jazbutyte V, Neyses L: Estrogen effects in the myocardium: inhibition of NF-κB DNA binding by estrogen receptor-α and -β. Biochem Biophys Res Commun 2001;286:1153-1157.
375. Chadwick CC, Chippari S, Matelan E, et al: Identification of pathway-selective estrogen receptor ligands that inhibit NF-κB transcriptional activity. Proc Natl Acad Sci USA 2005;102:2543-2548.
376. Piotrowski PC, Kwintkiewicz J, Rzepczynska IJ, et al: Statins inhibit growth of human endometrial stromal cells independently of cholesterol availability. Biol Reprod 2006;75:107-111.
377. Inoue I, Itoh F, Aoyagi S, et al: Fibrate and statin synergistically increase the transcriptional activities of PPARα/RXRα and decrease the transactivation of NFκB. Biochem Biophys Res Commun 2002;290:131-139.
378. Lin R, Liu J, Peng N, Yang G, Gan W, Wang W: Lovastatin reduces nuclear factor κB activation induced by C-reactive protein in human vascular endothelial cells. Biol Pharm Bull 2005;28:1630-1634.
379. Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W: Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005;26:423-438.
380. Attia GR, Zeitoun K, Edwards D, Johns A, Carr BR, Bulun SE: Progesterone receptor isoform A but not B is expressed in endometriosis. J Clin Endocrinol Metab 2000;85:2897-2902.
381. Takayama K, Zeitoun K, Gunby RT, Sasano H, Carr BR, Bulun SE: Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril 1998;69:709-713.
382. Razzi S, Fava A, Sartini A, De Simone S, Cobellis L, Petraglia F: Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovariectomised woman. BJOG 2004;111:182-184.
383. Shippen ER, West WJ Jr: Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil Steril 2004;81:1395-1398.
384. Ailawadi RK, Jobanputra S, Kataria M, Gurates B, Bulun SE: Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril 2004;81:290-296.
385. Amsterdam LL, Gentry W, Jobanputra S, Wolf M, Rubin SD, Bulun SE: Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril 2005;84:300-304.
386. Soysal S, Soysal ME, Ozer S, Gul N, Gezgin T: The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod 2004;19:160-167.
387. Monks NR, Biswas DK, Pardee AB: Blocking anti-apoptosis as a strategy for cancer chemotherapy: NF-κB as a target. J Cell Biochem 2004;92:646-650.
388. Ravi R, Bedi A: NF-κB in cancer - a friend turned foe. Drug Resist Updat 2004;7:53-67.
389. Karin M, Yamamoto Y, Wang QM: The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
390. Orlowski RZ, Baldwin AS Jr: NF-κB as a therapeutic target in cancer. Trends Mol Med 2002;8:385-389.
391. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-4427.
392. Frelin C, Imbert V, Griessinger E, Loubat A, Dreano M, Peyron JF: AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-α in Jurkat leukemic cells. Oncogene 2003;22:8187-8194.
393. Greene WC, Chen LF: Regulation of NF-κB action by reversible acetylation. Novartis Found Symp 2004;259:208-217; discussion 18-25.
394. Ziegler EC, Ghosh S: Regulating inducible transcription through controlled localization. Sci STKE 2005;2005:re6.
395. Gogusev J, Bouquet de Joliniere J, Telvi L, et al: Detection of DNA copy number changes in human endometriosis by comparative genomic hybridization. Hum Genet 1999;105:444-451.
396. Bulun SE, Imir G, Utsunomiya H, et al: Aromatase in endometriosis and uterine leiomyomata. J Steroid Biochem Mol Biol 2005;95:57-62.
397. Vercellini P, Cortesi I, Crosignani PG: Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril 1997;68:393-401.
398. Roy D, Liehr JG: Estrogen, DNA damage and mutations. Mutat Res 1999;424:107-115.
399. Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D: Estrogens as endogenous genotoxic agents - DNA adducts and mutations. J Natl Cancer Inst Monogr 2000;27:75-93.
400. Duesberg P, Rausch C, Rasnick D, Hehlmann R: Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci USA 1998;95:13692-13697.
401. Rasnick D, Duesberg PH: How aneuploidy affects metabolic control and causes cancer. Biochem J 1999;340(pt 3):621-630.
402. Fabarius A, Hehlmann R, Duesberg PH: Instability of chromosome structure in cancer cells increases exponentially with degrees of aneuploidy. Cancer Genet Cytogenet 2003;143:59-72.
403. Eden A, Gaudet F, Waghmare A, Jaenisch R: Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003;300:455.
404. Gaudet F, Hodgson JG, Eden A, et al: Induction of tumors in mice by genomic hypomethylation. Science 2003;300:489-492.
405. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R: DNA hypomethylation leads to elevated mutation rates. Nature 1998;395:89-93.
406. Dodge JE, Okano M, Dick F, et al: Inactivation of Dnmt3b in mouse embryonic fibroblasts results in DNA hypomethylation, chromosomal instability, and spontaneous immortalization. J Biol Chem 2005;280:17986-17991.
407. Kanai Y, Ushijima S, Tsuda H, Sakamoto M, Hirohashi S: Aberrant DNA methylation precedes loss of heterozygosity on chromosome 16 in chronic hepatitis and liver cirrhosis. Cancer Lett 2000;148:73-80.
408. Jones PA, Laird PW: Cancer epigenetics comes of age. Nat Genet 1999;21:163-167.
409. Wu Y, Halverson G, Basir Z, Strawn Y, Yan P, Guo SW: Aberrant methylation at HOXA10 may be responsible for Its aberrant expression in the endometrium of patients with endometriosis. Am J Obstet Gynecol 2005;193:371-380.
410. Wu Y, Strawn E, Basir Z, Halverson G, Guo SW: Aberrant expression of deoxyribonucleic acid methyltransferases DNMT1, DNMT3A and DNMT3B in women with endometriosis. Fertil Steril 2006;62:148-159.
411. Tamura M, Deb S, Sebastian S, Okamura K, Bulun SE: Estrogen up-regulates cyclooxygenase-2 via estrogen receptor in human uterine microvascular endothelial cells. Fertil Steril 2004;81:1351-1356.
412. Plummer SM, Holloway KA, Manson MM, et al: Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signalling complex. Oncogene 1999;18:6013-6020.
413. Singh S, Aggarwal BB: Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 1995;270:24995-25000.
414. Singh S, Natarajan K, Aggarwal BB: Capsaicin (8-methyl-N-vanillyl-6- nonenamide) is a potent inhibitor of nuclear transcription factor-κB activation by diverse agents. J Immunol 1996;157:4412-4420.
415. Aggarwal BB, Ichikawa H, Garodia P, et al: From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer. Expert Opin Ther Targets 2006;10:87-118.
416. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
417. Chen JW, Chen YH, Lin FY, Chen YL, Lin SJ: Ginkgo biloba extract inhibits tumor necrosis factor-α-induced reactive oxygen species generation, transcription factor activation, and cell adhesion molecule expression in human aortic endothelial cells. Arterioscler Thromb Vasc Biol 2003;23:1559-1566.
418. Carluccio MA, Siculella L, Ancora MA, et al: Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals. Arterioscler Thromb Vasc Biol 2003;23:622-629.
419. Ryan IP, Schriock ED, Taylor RN: Isolation, characterization, and comparison of human endometrial and endometriosis cells in vitro. J Clin Endocriol Metab 1994;78:642-649.